Search results
Found 547 matches for
Exogene, a pioneer in the use of generative artificial intelligence (AI) for T-cell receptor (TCR) engineering, has entered into a research collaboration with industry leader Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases.
